SlideShare ist ein Scribd-Unternehmen logo
1 von 78
Cytomegalovirus and cancer-specific immunity –  lessons from across the spectrum of immunodominance Paul Moss School of Cancer Sciences
Overview ,[object Object],[object Object],[object Object],[object Object],[object Object]
- HIV+ donors - Cloned HIV-specific CTL - Cloned TCR - cDNA from PBMC was probed with oligos for TCRs - Suggested effector frequency of 0.2 - 1%
Led to collaboration on use of new reagents to study T cell immune responses Viral Antigen Fluorescence T Cell
We could visualise HIV-specific T cells Altman, Moss et al Science. 1996 Oct 4;274(5284):94-6.Phenotypic analysis of antigen-specific T lymphocytes.
Then used cytomegalovirus as a ‘control’ for HIV ,[object Object]
Herpes viruses Group of eight viruses HSV I & II,  EBV,  VZV,  CMV,  HHV-6 HHV-7, HHV-8
CMV infection is very common
CMV natural history ,[object Object],[object Object],[object Object],[object Object]
CMV latency appears to be the result of chronic immune control Antibody NK cells T cells
T cell immunity in healthy donors
The CD8+ T cell response to CMV
Age Percentage of CD8+ T cell response Khan et al , J.I. 2004 The CD8-specific T cell response to CMV increases with age DE  F P=0.0352 P0.0067 P=0.0159 P=0.07262 P=0.003
How does CMV change the  memory  and  naïve  T cell count in healthy people ? T cells Naive Memory
The CD8+ memory T cell count is stable with age
CMV greatly increases the number of memory T cells
The CD8+ naïve T cell count declines with age
CMV reduces the naïve cell count at all ages
CMV seropositivity at age 50 years accelerates naïve T cell decline by 25 years
The immune response to CMV is massive ,[object Object],[object Object],Time (years) Magnitude of T cell immunity CMV
The clinical implications of CMV infection
Primary infection Time (years) Magnitude of T cell immunity
Sometimes the initial (primary) infection with CMV can cause clinical problems “  I though it was the end of my tennis. Even as a person I could feel myself changing. I just wanted to stay and home and not see anyone, not even my friends. But slowly I got better. I still have to be careful and I can’t train or work as hard as I once did” Justine Henin-Hardenne
Immune senescence Time (years) Magnitude of T cell immunity
Does CMV infection contribute to immune senescence ?
Elderly individuals who are CMV seropositive die 4.5 years earlier than uninfected individuals
CMV-specific immunity in immunosuppressed patients
CMV was a major cause of death in the early days of stem cells transplantation CMV pneumonitis
Patients have very few CMV-specific T cells in the first three months following SCT Time post-SCT  Number of CMV-specific T cells
Is it possible to transfer T cells into the patient to correct the early period of immunodeficiency ? CMV-specific T cells
BMT is the ideal setting for adoptive transfer of T cells D D P P Time Following SCT, the patient is immunologically tolerant of cells taken from the donor
Use tetramers to bind to CMV-specific T cells in the donor Stain T cells FACS analysis T Cell PE
T cells that bind tetramer can be selected with magnetic beads T Cell PE
Transferred T cells can  expand  and  clear  CMV viraemia ( Cobbold et al, JEM 2005) 2.10 6  CMV-specific T cells were given 99.5% Pre-infusion blood sample 0% •  Prior to infusion the patient had  CMV viraemia •  No CMV-specific T cells were  present 0.5% 9 days later T cells were present  and  the patient became CMV negative Blood sample 9 days after infusion
 
 
 
 
What can we do to control CMV?  ,[object Object],[object Object],[object Object],[object Object],[object Object]
Do we want to eradicate CMV ?
Could CMV have beneficial effects ? ,[object Object],[object Object],[object Object]
What is  homo sapiens ? + + + 10 14  cells 10 15  cells a lot..
Conclusions - Cytomegalovirus ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
The immune response to cancer
 
 
Cancer Testis Antigens (CTAgs) ,[object Object],[object Object]
MAGE-1 immunohistochemistry stain of human testis – Old LJ (2003)
testis ovary trophoblast Bladder cancer
Cancer-testis Antigens (CTAgs) in cancer ,[object Object],[object Object],[object Object],[object Object]
Tumour regression following vaccination MAGE antigens in a melanoma patient  Evolution of skin metastases on the leg of patient EB81 during treatment.  van Baren   N  et al 2005   (A) (B) (C) (A) Before vaccination (B) After four vaccinations with ALVAC (after 3 months) (C) After 10 months
MAGE proteins are expressed in myeloma   ,[object Object]
[object Object],[object Object],Study of the CD8+ T cell response to CTAg in Multiple Myeloma
PBMCs only PBMCs + RVRF PRE POST 0.05% 0.01% 0.00008   0.004   Example of CTAg-specific cell responses in myeloma CD8 IFN 
[object Object],CTAg-specific CD8+ T cell immunity in myeloma patients Goodyear et al 2005, 2008
Technical issues ,[object Object],[object Object],[object Object],[object Object]
Question concerning this T cell response ,[object Object],[object Object],[object Object]
The CD8 response actually  increases  in the terminal stages of disease
MAGE   – specific CD8 T cell clones can kill tumour when they are cloned  in vitro (iii) (ii)
What about CD4 cells ?
Multiple myeloma has a pre-malignant phase ,[object Object],[object Object],[object Object],[object Object]
Strong CD4+ responses can been seen in MGUS Pre-sort Post-sort DMSO  MAGE-A3 149-160  MAGE-A3 243-258   MAGE-A3 281-295 MAGE-A1/A3 121-134 / MAGE-A3 191-205 SEB
CD4 and CD8 responses show a different pattern in MGUS and myeloma Multiple Myeloma   MGUS Positive Negative Positive Negative CD4 1 29 4 26 CD8 13 42 1 weak 20
Does CD4+ T cell immunity play a role in controlling the progression of MGUS ? ,[object Object],[object Object]
CD4 CD8
CD4 immunity may determine the efficacy of the immune response CD4
The balance of  inflammatory  and  regulatory  CD4 immunity may be critical Th1 - IFN  Treg - suppression CD4 CD4
Th1 - IFN  Treg - suppression CD4 CD4
Th1 - IFN  Treg - suppression CD4 CD4
Pattern of CTAg immunity ,[object Object],[object Object],[object Object]
2000- renal transplant patient developed melanoma in kidney and breast 2000 - another transplant patient 2 developed melanoma in kidney - Registry showed both patients had been transplanted from same patient in 1998 - This patient had received excision of 2.6mm melanoma in 1982 Tumour latency Mackie 2003
Challenges ,[object Object],[object Object],[object Object]
Conclusions ,[object Object],[object Object],[object Object]
Acknowledgements ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
 
 
 

Weitere ähnliche Inhalte

Was ist angesagt?

Immunology of tanslanatation and malignancy
Immunology of tanslanatation and malignancyImmunology of tanslanatation and malignancy
Immunology of tanslanatation and malignancy
raghunathp
 
Presentation by adrian hill [university of oxford]
Presentation by adrian hill [university of oxford]Presentation by adrian hill [university of oxford]
Presentation by adrian hill [university of oxford]
Pamoja
 
Monoclonal Antibodies As Therapeutic Agents In Oncology And
Monoclonal Antibodies As Therapeutic Agents In Oncology AndMonoclonal Antibodies As Therapeutic Agents In Oncology And
Monoclonal Antibodies As Therapeutic Agents In Oncology And
drmisbah83
 
Transplantation and tumor immunology
Transplantation and tumor immunologyTransplantation and tumor immunology
Transplantation and tumor immunology
Bruno Mmassy
 
J immunol 2003-harshyne-2302-9
J immunol 2003-harshyne-2302-9J immunol 2003-harshyne-2302-9
J immunol 2003-harshyne-2302-9
Elsa von Licy
 
CCO immune checkpoint_inhibitors_in_cancer_care
CCO immune checkpoint_inhibitors_in_cancer_careCCO immune checkpoint_inhibitors_in_cancer_care
CCO immune checkpoint_inhibitors_in_cancer_care
Adonis Guancia
 

Was ist angesagt? (20)

Immunology of tanslanatation and malignancy
Immunology of tanslanatation and malignancyImmunology of tanslanatation and malignancy
Immunology of tanslanatation and malignancy
 
Transplantation immunology dr. ihsan alsaimary
Transplantation immunology dr. ihsan alsaimaryTransplantation immunology dr. ihsan alsaimary
Transplantation immunology dr. ihsan alsaimary
 
Presentation by adrian hill [university of oxford]
Presentation by adrian hill [university of oxford]Presentation by adrian hill [university of oxford]
Presentation by adrian hill [university of oxford]
 
Malaria
MalariaMalaria
Malaria
 
Monoclonal Antibodies As Therapeutic Agents In Oncology And
Monoclonal Antibodies As Therapeutic Agents In Oncology AndMonoclonal Antibodies As Therapeutic Agents In Oncology And
Monoclonal Antibodies As Therapeutic Agents In Oncology And
 
Transplantation and tumor immunology
Transplantation and tumor immunologyTransplantation and tumor immunology
Transplantation and tumor immunology
 
2015 11 Inmunoterapia en nsclc
2015 11 Inmunoterapia en nsclc2015 11 Inmunoterapia en nsclc
2015 11 Inmunoterapia en nsclc
 
Therapeutic antibodies 5_humanization
Therapeutic antibodies 5_humanizationTherapeutic antibodies 5_humanization
Therapeutic antibodies 5_humanization
 
Ppat.1005652
Ppat.1005652Ppat.1005652
Ppat.1005652
 
Tumour and transplant immunology.pptx seminar 4
Tumour and transplant immunology.pptx seminar 4Tumour and transplant immunology.pptx seminar 4
Tumour and transplant immunology.pptx seminar 4
 
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...
Paludisme grave : pourquoi doit-on développer des modèles in vitro sur le ter...
 
Tumour immunology
Tumour immunologyTumour immunology
Tumour immunology
 
Cell-based Assays for Immunotherapy Drug Development
Cell-based Assays for Immunotherapy Drug DevelopmentCell-based Assays for Immunotherapy Drug Development
Cell-based Assays for Immunotherapy Drug Development
 
J immunol 2003-harshyne-2302-9
J immunol 2003-harshyne-2302-9J immunol 2003-harshyne-2302-9
J immunol 2003-harshyne-2302-9
 
Journal club_NKs CXCR2 gene modified - improved migration
Journal club_NKs CXCR2 gene modified - improved migrationJournal club_NKs CXCR2 gene modified - improved migration
Journal club_NKs CXCR2 gene modified - improved migration
 
Dr. David Mooney - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. David Mooney - Simposio Internacional 'Terapias oncológicas avanzadas'Dr. David Mooney - Simposio Internacional 'Terapias oncológicas avanzadas'
Dr. David Mooney - Simposio Internacional 'Terapias oncológicas avanzadas'
 
Diagnóstico funcional y genético de las inmunodeficiencias primarias
Diagnóstico funcional y genético de las inmunodeficiencias primariasDiagnóstico funcional y genético de las inmunodeficiencias primarias
Diagnóstico funcional y genético de las inmunodeficiencias primarias
 
CCO immune checkpoint_inhibitors_in_cancer_care
CCO immune checkpoint_inhibitors_in_cancer_careCCO immune checkpoint_inhibitors_in_cancer_care
CCO immune checkpoint_inhibitors_in_cancer_care
 
Crosstalk Between Cancer Inflammation and Immunity: Host Defense Webinar Seri...
Crosstalk Between Cancer Inflammation and Immunity: Host Defense Webinar Seri...Crosstalk Between Cancer Inflammation and Immunity: Host Defense Webinar Seri...
Crosstalk Between Cancer Inflammation and Immunity: Host Defense Webinar Seri...
 
Wong raymond symposium2016_present
Wong raymond symposium2016_presentWong raymond symposium2016_present
Wong raymond symposium2016_present
 

Ähnlich wie ProImmune Antigen Characterization Summit Paul Moss

tumor immunology.pptx
tumor immunology.pptxtumor immunology.pptx
tumor immunology.pptx
Annie Annie
 
Tumour immunology leture notes
Tumour immunology leture notesTumour immunology leture notes
Tumour immunology leture notes
Bruno Mmassy
 
Cancer Immunology and Immunotherapy in Treatment of High Grade Glial Tumors
Cancer Immunology and Immunotherapy in Treatment of High Grade Glial TumorsCancer Immunology and Immunotherapy in Treatment of High Grade Glial Tumors
Cancer Immunology and Immunotherapy in Treatment of High Grade Glial Tumors
NeuroAcademy
 
Krug l.m.-et-al.-2010-cancer-immunology-immunotherapy
Krug l.m.-et-al.-2010-cancer-immunology-immunotherapyKrug l.m.-et-al.-2010-cancer-immunology-immunotherapy
Krug l.m.-et-al.-2010-cancer-immunology-immunotherapy
SellasCorp
 

Ähnlich wie ProImmune Antigen Characterization Summit Paul Moss (20)

Tumor immunology dr. ihsan alsaimary
Tumor immunology  dr. ihsan alsaimaryTumor immunology  dr. ihsan alsaimary
Tumor immunology dr. ihsan alsaimary
 
tumor immunology.pptx
tumor immunology.pptxtumor immunology.pptx
tumor immunology.pptx
 
Immunotherapy and gene therapy
Immunotherapy and gene therapyImmunotherapy and gene therapy
Immunotherapy and gene therapy
 
Immune response against tumors
Immune response against tumorsImmune response against tumors
Immune response against tumors
 
Tumor immunology
Tumor immunologyTumor immunology
Tumor immunology
 
Tumour immunology leture notes
Tumour immunology leture notesTumour immunology leture notes
Tumour immunology leture notes
 
Cancer Immunotherapy and Gene Therapy
Cancer Immunotherapy and Gene TherapyCancer Immunotherapy and Gene Therapy
Cancer Immunotherapy and Gene Therapy
 
Tumourclasss
TumourclasssTumourclasss
Tumourclasss
 
14.tumor immunology and immunotherapy
14.tumor  immunology and immunotherapy14.tumor  immunology and immunotherapy
14.tumor immunology and immunotherapy
 
5 tumor biotherapy
5 tumor biotherapy5 tumor biotherapy
5 tumor biotherapy
 
Cancer immunology.pptx
Cancer immunology.pptxCancer immunology.pptx
Cancer immunology.pptx
 
Active Immunotherapy in cancer – Current Status_Crimson Publishers
Active Immunotherapy in cancer – Current Status_Crimson PublishersActive Immunotherapy in cancer – Current Status_Crimson Publishers
Active Immunotherapy in cancer – Current Status_Crimson Publishers
 
Immunological Checkpoints and Cancer Immunotherapy
Immunological Checkpoints and Cancer ImmunotherapyImmunological Checkpoints and Cancer Immunotherapy
Immunological Checkpoints and Cancer Immunotherapy
 
MSI 825Tumor Immunology (1).pptx
MSI 825Tumor Immunology (1).pptxMSI 825Tumor Immunology (1).pptx
MSI 825Tumor Immunology (1).pptx
 
Cancer Immunology and Immunotherapy in Treatment of High Grade Glial Tumors
Cancer Immunology and Immunotherapy in Treatment of High Grade Glial TumorsCancer Immunology and Immunotherapy in Treatment of High Grade Glial Tumors
Cancer Immunology and Immunotherapy in Treatment of High Grade Glial Tumors
 
ROLE OF IMMUNE CELLS IN CANCER AND TARGETING IMMUNE CELLS FOR CANCER THERAPY
ROLE OF IMMUNE CELLS IN CANCER AND TARGETING IMMUNE CELLS FOR CANCER THERAPYROLE OF IMMUNE CELLS IN CANCER AND TARGETING IMMUNE CELLS FOR CANCER THERAPY
ROLE OF IMMUNE CELLS IN CANCER AND TARGETING IMMUNE CELLS FOR CANCER THERAPY
 
Immunotherapy beyond checkpoints inhibitors
Immunotherapy beyond checkpoints inhibitorsImmunotherapy beyond checkpoints inhibitors
Immunotherapy beyond checkpoints inhibitors
 
Krug l.m.-et-al.-2010-cancer-immunology-immunotherapy
Krug l.m.-et-al.-2010-cancer-immunology-immunotherapyKrug l.m.-et-al.-2010-cancer-immunology-immunotherapy
Krug l.m.-et-al.-2010-cancer-immunology-immunotherapy
 
tumor immunology ........by Dr Palak.pptx
tumor immunology ........by Dr Palak.pptxtumor immunology ........by Dr Palak.pptx
tumor immunology ........by Dr Palak.pptx
 
Cancer Immunotherapy from Bench to Clinic_Mohamed Labib Salem ,ppt
Cancer Immunotherapy from Bench to Clinic_Mohamed Labib Salem ,pptCancer Immunotherapy from Bench to Clinic_Mohamed Labib Salem ,ppt
Cancer Immunotherapy from Bench to Clinic_Mohamed Labib Salem ,ppt
 

Kürzlich hochgeladen

+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
?#DUbAI#??##{{(☎️+971_581248768%)**%*]'#abortion pills for sale in dubai@
 
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers:  A Deep Dive into Serverless Spatial Data and FMECloud Frontiers:  A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Safe Software
 

Kürzlich hochgeladen (20)

+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
 
Manulife - Insurer Innovation Award 2024
Manulife - Insurer Innovation Award 2024Manulife - Insurer Innovation Award 2024
Manulife - Insurer Innovation Award 2024
 
Apidays Singapore 2024 - Building Digital Trust in a Digital Economy by Veron...
Apidays Singapore 2024 - Building Digital Trust in a Digital Economy by Veron...Apidays Singapore 2024 - Building Digital Trust in a Digital Economy by Veron...
Apidays Singapore 2024 - Building Digital Trust in a Digital Economy by Veron...
 
Tata AIG General Insurance Company - Insurer Innovation Award 2024
Tata AIG General Insurance Company - Insurer Innovation Award 2024Tata AIG General Insurance Company - Insurer Innovation Award 2024
Tata AIG General Insurance Company - Insurer Innovation Award 2024
 
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers:  A Deep Dive into Serverless Spatial Data and FMECloud Frontiers:  A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
 
Axa Assurance Maroc - Insurer Innovation Award 2024
Axa Assurance Maroc - Insurer Innovation Award 2024Axa Assurance Maroc - Insurer Innovation Award 2024
Axa Assurance Maroc - Insurer Innovation Award 2024
 
Artificial Intelligence Chap.5 : Uncertainty
Artificial Intelligence Chap.5 : UncertaintyArtificial Intelligence Chap.5 : Uncertainty
Artificial Intelligence Chap.5 : Uncertainty
 
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost Saving
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost SavingRepurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost Saving
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost Saving
 
presentation ICT roal in 21st century education
presentation ICT roal in 21st century educationpresentation ICT roal in 21st century education
presentation ICT roal in 21st century education
 
HTML Injection Attacks: Impact and Mitigation Strategies
HTML Injection Attacks: Impact and Mitigation StrategiesHTML Injection Attacks: Impact and Mitigation Strategies
HTML Injection Attacks: Impact and Mitigation Strategies
 
Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...
Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...
Mastering MySQL Database Architecture: Deep Dive into MySQL Shell and MySQL R...
 
2024: Domino Containers - The Next Step. News from the Domino Container commu...
2024: Domino Containers - The Next Step. News from the Domino Container commu...2024: Domino Containers - The Next Step. News from the Domino Container commu...
2024: Domino Containers - The Next Step. News from the Domino Container commu...
 
A Domino Admins Adventures (Engage 2024)
A Domino Admins Adventures (Engage 2024)A Domino Admins Adventures (Engage 2024)
A Domino Admins Adventures (Engage 2024)
 
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
 
From Event to Action: Accelerate Your Decision Making with Real-Time Automation
From Event to Action: Accelerate Your Decision Making with Real-Time AutomationFrom Event to Action: Accelerate Your Decision Making with Real-Time Automation
From Event to Action: Accelerate Your Decision Making with Real-Time Automation
 
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot TakeoffStrategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
Strategize a Smooth Tenant-to-tenant Migration and Copilot Takeoff
 
How to Troubleshoot Apps for the Modern Connected Worker
How to Troubleshoot Apps for the Modern Connected WorkerHow to Troubleshoot Apps for the Modern Connected Worker
How to Troubleshoot Apps for the Modern Connected Worker
 
Deploy with confidence: VMware Cloud Foundation 5.1 on next gen Dell PowerEdg...
Deploy with confidence: VMware Cloud Foundation 5.1 on next gen Dell PowerEdg...Deploy with confidence: VMware Cloud Foundation 5.1 on next gen Dell PowerEdg...
Deploy with confidence: VMware Cloud Foundation 5.1 on next gen Dell PowerEdg...
 
The 7 Things I Know About Cyber Security After 25 Years | April 2024
The 7 Things I Know About Cyber Security After 25 Years | April 2024The 7 Things I Know About Cyber Security After 25 Years | April 2024
The 7 Things I Know About Cyber Security After 25 Years | April 2024
 
Real Time Object Detection Using Open CV
Real Time Object Detection Using Open CVReal Time Object Detection Using Open CV
Real Time Object Detection Using Open CV
 

ProImmune Antigen Characterization Summit Paul Moss

  • 1. Cytomegalovirus and cancer-specific immunity – lessons from across the spectrum of immunodominance Paul Moss School of Cancer Sciences
  • 2.
  • 3. - HIV+ donors - Cloned HIV-specific CTL - Cloned TCR - cDNA from PBMC was probed with oligos for TCRs - Suggested effector frequency of 0.2 - 1%
  • 4. Led to collaboration on use of new reagents to study T cell immune responses Viral Antigen Fluorescence T Cell
  • 5. We could visualise HIV-specific T cells Altman, Moss et al Science. 1996 Oct 4;274(5284):94-6.Phenotypic analysis of antigen-specific T lymphocytes.
  • 6.
  • 7. Herpes viruses Group of eight viruses HSV I & II, EBV, VZV, CMV, HHV-6 HHV-7, HHV-8
  • 8. CMV infection is very common
  • 9.
  • 10. CMV latency appears to be the result of chronic immune control Antibody NK cells T cells
  • 11. T cell immunity in healthy donors
  • 12. The CD8+ T cell response to CMV
  • 13. Age Percentage of CD8+ T cell response Khan et al , J.I. 2004 The CD8-specific T cell response to CMV increases with age DE F P=0.0352 P0.0067 P=0.0159 P=0.07262 P=0.003
  • 14. How does CMV change the memory and naïve T cell count in healthy people ? T cells Naive Memory
  • 15. The CD8+ memory T cell count is stable with age
  • 16. CMV greatly increases the number of memory T cells
  • 17. The CD8+ naïve T cell count declines with age
  • 18. CMV reduces the naïve cell count at all ages
  • 19. CMV seropositivity at age 50 years accelerates naïve T cell decline by 25 years
  • 20.
  • 21. The clinical implications of CMV infection
  • 22. Primary infection Time (years) Magnitude of T cell immunity
  • 23. Sometimes the initial (primary) infection with CMV can cause clinical problems “ I though it was the end of my tennis. Even as a person I could feel myself changing. I just wanted to stay and home and not see anyone, not even my friends. But slowly I got better. I still have to be careful and I can’t train or work as hard as I once did” Justine Henin-Hardenne
  • 24. Immune senescence Time (years) Magnitude of T cell immunity
  • 25. Does CMV infection contribute to immune senescence ?
  • 26. Elderly individuals who are CMV seropositive die 4.5 years earlier than uninfected individuals
  • 27. CMV-specific immunity in immunosuppressed patients
  • 28. CMV was a major cause of death in the early days of stem cells transplantation CMV pneumonitis
  • 29. Patients have very few CMV-specific T cells in the first three months following SCT Time post-SCT Number of CMV-specific T cells
  • 30. Is it possible to transfer T cells into the patient to correct the early period of immunodeficiency ? CMV-specific T cells
  • 31. BMT is the ideal setting for adoptive transfer of T cells D D P P Time Following SCT, the patient is immunologically tolerant of cells taken from the donor
  • 32. Use tetramers to bind to CMV-specific T cells in the donor Stain T cells FACS analysis T Cell PE
  • 33. T cells that bind tetramer can be selected with magnetic beads T Cell PE
  • 34. Transferred T cells can expand and clear CMV viraemia ( Cobbold et al, JEM 2005) 2.10 6 CMV-specific T cells were given 99.5% Pre-infusion blood sample 0% •  Prior to infusion the patient had CMV viraemia •  No CMV-specific T cells were present 0.5% 9 days later T cells were present and the patient became CMV negative Blood sample 9 days after infusion
  • 35.  
  • 36.  
  • 37.  
  • 38.  
  • 39.
  • 40. Do we want to eradicate CMV ?
  • 41.
  • 42. What is homo sapiens ? + + + 10 14 cells 10 15 cells a lot..
  • 43.
  • 44. The immune response to cancer
  • 45.  
  • 46.  
  • 47.
  • 48. MAGE-1 immunohistochemistry stain of human testis – Old LJ (2003)
  • 49. testis ovary trophoblast Bladder cancer
  • 50.
  • 51. Tumour regression following vaccination MAGE antigens in a melanoma patient Evolution of skin metastases on the leg of patient EB81 during treatment. van Baren N et al 2005 (A) (B) (C) (A) Before vaccination (B) After four vaccinations with ALVAC (after 3 months) (C) After 10 months
  • 52.
  • 53.
  • 54. PBMCs only PBMCs + RVRF PRE POST 0.05% 0.01% 0.00008 0.004 Example of CTAg-specific cell responses in myeloma CD8 IFN 
  • 55.
  • 56.
  • 57.
  • 58. The CD8 response actually increases in the terminal stages of disease
  • 59. MAGE – specific CD8 T cell clones can kill tumour when they are cloned in vitro (iii) (ii)
  • 60. What about CD4 cells ?
  • 61.
  • 62. Strong CD4+ responses can been seen in MGUS Pre-sort Post-sort DMSO MAGE-A3 149-160 MAGE-A3 243-258 MAGE-A3 281-295 MAGE-A1/A3 121-134 / MAGE-A3 191-205 SEB
  • 63. CD4 and CD8 responses show a different pattern in MGUS and myeloma Multiple Myeloma MGUS Positive Negative Positive Negative CD4 1 29 4 26 CD8 13 42 1 weak 20
  • 64.
  • 66. CD4 immunity may determine the efficacy of the immune response CD4
  • 67. The balance of inflammatory and regulatory CD4 immunity may be critical Th1 - IFN  Treg - suppression CD4 CD4
  • 68. Th1 - IFN  Treg - suppression CD4 CD4
  • 69. Th1 - IFN  Treg - suppression CD4 CD4
  • 70.
  • 71. 2000- renal transplant patient developed melanoma in kidney and breast 2000 - another transplant patient 2 developed melanoma in kidney - Registry showed both patients had been transplanted from same patient in 1998 - This patient had received excision of 2.6mm melanoma in 1982 Tumour latency Mackie 2003
  • 72.
  • 73.
  • 74.
  • 75.  
  • 76.  
  • 77.  
  • 78.  

Hinweis der Redaktion

  1. If an antigen which had been labelled, for instance with a fluorescent dye, could be directly bound to T cells then the antigen-specific cells could be detected directly.
  2. Once these complexes are made they can bind to a T cell specific for the peptide which was been inserted in the multimeric complex and then these T cells can be detected on a FACS machine by the fluoresecnce that they emit.
  3. Once these complexes are made they can bind to a T cell specific for the peptide which was been inserted in the multimeric complex and then these T cells can be detected on a FACS machine by the fluoresecnce that they emit.